TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02444819
Drug: HM61713
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM61713 will be administered to evaluate efficacy and safety of subjects.
Study: NCT00009815
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02528097
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline)
Study: NCT02316756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo which will be given as oral suspension
Study: NCT03811678
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet，administered orally once daily
Study: NCT02934412
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
Study: NCT04425772
Drug: FNC+Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
Study: NCT04425772
Drug: FNC dummy tablet+Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
Study: NCT03631862
Drug: CHOP Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
Study: NCT03029650
Drug: Transderm Scop®
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDDS dosage is 1.5 mg/72 hrs
Study: NCT00696865
Drug: AZD2624
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension, 3 doses
Study: NCT00696865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01187901
Drug: Sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
Study: NCT01187901
Drug: Placebo A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
Study: NCT01187901
Drug: Placebo B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
Study: NCT01982604
Drug: TI-Inhalation Powder A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Insulin
Study: NCT01588145
Drug: HM61713
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
Study: NCT03816306
Drug: LCZ 696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
Study: NCT00920608
Drug: AZD9056
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral use. 400 mg once daily for 7 days
Study: NCT00920608
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
Study: NCT01613014
Drug: ABT-436
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target dose - 400mg BID
Study: NCT01613014
Drug: Matched Placebo - Sugar Pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Dose - 2 pills BID
Study: NCT01064024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, every 8 hours for 48 hours
Study: NCT00003662
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00809172
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
Study: NCT00711269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00537550
Drug: Vincristin, Daunorubicine, Asparaginase, Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy
Study: NCT01822041
Drug: ARN-509
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 240 mg ARN-509
Study: NCT01266655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00385567
Drug: PEHRG214
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00926796
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Four 500 mg tablets will be administered orally to equal a 2 gm dose.
Study: NCT00926796
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose of 240 mg intramuscular one time for patients \>45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
Study: NCT01720615
Drug: Propofol / Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia: Loss of consciousness and standard clinical practice
Study: NCT01720615
Drug: Sevoflurane / Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia: Loss of consciousness and standard clinical practice
Study: NCT02840058
Drug: Anti PD1/PDL1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03218254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01552928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide placebo + Moxifloxacin placebo single oral dose
Study: NCT03105596
Drug: Chidamide plus DICE Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
Study: NCT03064295
Drug: Contrast
Normalized name: CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
Study: NCT03064295
Drug: Pharmacologic Stress Agent
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
Study: NCT04570657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive multiple doses of placebo
Study: NCT00631657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet once a day
Study: NCT00761657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT02307721
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
Study: NCT03593538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose filler in gel capsules
Study: NCT02998554
Drug: SHP640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
Study: NCT02998554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
Study: NCT01176097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension,single doses
Study: NCT01717664
Drug: RHB-104
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
Study: NCT00859781
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
Study: NCT01008995
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection at Week 0 and 4
Study: NCT01008995
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection at Week 12
Study: NCT04584112
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.
Study: NCT01679080
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: antiresorptive and calcium and vitamin D
Study: NCT04584112
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.
Study: NCT00251407
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
Study: NCT01589718
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
Study: NCT02645903
Drug: standard general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cases to whom applied alone standard general anesthesia were determined as Group 2
Study: NCT01883323
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: i.v., 60mg/kg per day for 2 days
Study: NCT01208038
Drug: Intrinsa Transdermal testosterone patch
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
Study: NCT01966575
Drug: Progestin
Normalized name: Progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
Study: NCT03484299
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
Study: NCT02274506
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg by vein on Days -8 and -7.
Study: NCT05861297
Drug: Prednisolone and Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.
Study: NCT03050359
Drug: TAK-438 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets.
Study: NCT03050359
Drug: Bismuth-Containing Quadruple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Study: NCT00775502
Drug: BIW-8962
Normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
Study: NCT00649376
Drug: Allegra® Tablets 180 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180mg, single dose fasting
Study: NCT01371487
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/once-daily single doses on Day 1 of Periods 1 and 2
Study: NCT02753036
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
Study: NCT04336722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical in appearance to experimental drug (odevixibat).
Study: NCT03725202
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.
Study: NCT04536636
Drug: Control-No drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received usual medical care with no DHA
Study: NCT02304783
Drug: Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
Study: NCT02304783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
Study: NCT00264550
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive methotrexate capsules weekly.
Study: NCT00264550
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
Study: NCT01555112
Drug: Topical AS101
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
Study: NCT00264550
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo capsules weekly
Study: NCT02227017
Drug: TPV capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02227017
Drug: TPV solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02227017
Drug: RTV capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02227017
Drug: RTV solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03274492
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT03274492
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT03913221
Drug: Caffeine Citrate 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 5 mg/kg IV.
Study: NCT03913221
Drug: Caffeine Citrate 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 10 mg/kg IV.
Study: NCT00000542
Drug: chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000542
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01362803
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
Study: NCT04149899
Drug: WB007 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: WB007 Ophthalmic Solution 0.05%
Study: NCT04149899
Drug: WB007 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: WB007 Ophthalmic Solution 0.15%
Study: NCT04149899
Drug: WB007 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: WB007 Ophthalmic Solution 0.4%
Study: NCT00882726
Drug: CNTO 3649 SC (Diabetic patients)
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
Study: NCT00882726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
Study: NCT04185883
Drug: RMC-4630
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMC-4630 administered orally as a capsule.
Study: NCT01192906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses, once a day for 52 weeks
Study: NCT00976911
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/m2 iv every 4 weeks
Study: NCT01757782
Drug: Placebo (distilled water)
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distill water oral
Study: NCT00126399
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01580592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, s.c., every 4 weeks
Study: NCT00783341
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04043338
Drug: XC130-A10H
Approvals — FDA: no, EMA: no, PMDA: no
Description: XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
Study: NCT04043338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplied as matching capsules or tablets
Study: NCT04392102
Drug: ZL-2306(Niraparib）
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Study: NCT02985268
Drug: Optimal Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
Study: NCT04229498
Drug: Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
Study: NCT02945566
Drug: Long course concurrent chemoradiation with capecitabine and radiotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
Study: NCT00610727
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Placebo (0 mg)
Study: NCT03229408
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
Study: NCT02465060
Drug: Fexagratinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01327651
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
Study: NCT01327651
Drug: Time-driven dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC twice weekly with a post-exposure dose
Study: NCT04069156
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to either Placebo or Aspirin post implant
Study: NCT01994291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks
Study: NCT01994291
Drug: Masked Sham Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty, needle-less syringe is used by the unmasked team once a month.
Study: NCT01577589
Drug: Placebo in 50 ml infusion volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01577589
Drug: Placebo in 250 ml infusion volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01577589
Drug: Placebo in 100 ml infusion volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion